SCHEMBL7066967

SCHEMBL7066967

O=C(O)C1(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.59
USP2 O75604 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MMP1 P03956 7/20 0.48
MMP12 P39900 2/20 0.48
GAA P10253 2/20 0.48
MMP13 P45452 7/20 0.47
ADAMTS5 Q9UNA0 2/20 0.47
CYP1A2 P05177 1/20 0.47
PLG P00747 2/20 0.47
PLAU P00749 2/20 0.47
ADAMTS4 O75173 2/20 0.46
PLAT P00750 1/20 0.45
MMP2 P08253 4/20 0.44
MMP3 P08254 3/20 0.44
MMP9 P14780 3/20 0.44
MMP7 P09237 2/20 0.44
MMP8 P22894 1/20 0.44
MMP14 P50281 1/20 0.44
ADAM17 P78536 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5675304 0.91 USP2 (0.60) HTTUSP2SMN1; SMN2MMP1GAA
SCHEMBL14676227 0.89 USP2 (0.58) HTTUSP2SMN1; SMN2MMP1GAA
SCHEMBL6770734 0.89 USP2 (0.56) HTTUSP2SMN1; SMN2MMP1MMP13
SCHEMBL6766379 0.87 USP2 (0.54) HTTUSP2SMN1; SMN2MMP1MMP13
SCHEMBL14675849 0.86 USP2 (0.55) HTTUSP2SMN1; SMN2MMP1GAA
SCHEMBL7066448 0.85 MMP13 (0.62) HTTUSP2SMN1; SMN2MMP1MMP12
SCHEMBL7064268 0.84 HTT (0.60) HTTUSP2SMN1; SMN2MMP1GAA
SCHEMBL7065804 0.84 SMN1; SMN2 (0.60) HTTUSP2SMN1; SMN2MMP1GAA
SCHEMBL7067073 0.84 USP2 (0.67) HTTUSP2SMN1; SMN2MMP1MMP12
SCHEMBL7066058 0.84 USP2 (0.71) HTTUSP2SMN1; SMN2MMP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP claimed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 HTT 1221/4885USP2 1089/4885SMN1; SMN2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.